FRANKFURT, Jan 30 (Reuters) - Roche's CEO said

on Thursday that the Swiss drugs and diagnostics group's major

production sites in the United States prepare it well for the

prospect of trade tariffs raised by President Donald Trump.

"We have a significant manufacturing footprint in the U.S.

and we will continue to expand on that ... We are very well

positioned in this regard, whatever happens," CEO Thomas

Schinecker said in a media call.

He added that Roche had invested 11 billion Swiss francs

($12.1 billion) in the U.S. over the last 10 years and, with a

U.S. headcount of 25,000, it has more staff there than in

Switzerland and Germany combined.

($1 = 0.9067 Swiss francs)